Mesothelioma is a type of cancer that forms on the thin protective lining that cover the lungs and other internal organs. Mesothelioma is often associated with exposure to asbestos, but can occur in people who have not been exposed to asbestos The average age at diagnosis is 60 years old.
Newly diagnosed individuals with mesothelioma are often treated first with chemotherapy. However, for people with relapsed mesothelioma (when the disease returns) or refractory mesothelioma (resistant to prior treatment), there are currently no U.S. FDA approved treatment options.
A few genes have been discovered to be altered in mesothelioma, one of which is BAP1. Of the patients diagnosed with mesothelioma, 40-60% have mesothelioma characterized by the absense or abnormal function of BAP1*.
Clinical Trials in Mesothelioma
Epizyme is enrolling adult patients (18 years and older) with mesothelioma, particularly mesothelioma characterized by the absence or abnormal function in BAP1, that have relapsed (when the disease or symptoms returns) or is refractory (resistant) to prior treatment.
For more detailed information on this trial, please visit: https://clinicaltrials.gov/ct2/show/NCT02860286?term=EZH2&rank=3